Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.

Autor: Pudil R; 1st Department Medicine - Cardioangiology, Charles University Prague, Medical Faculty and University Hospital Hradec Kralove, Prague, Czech Republic., Mueller C; Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland., Čelutkienė J; Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.; State Research Institute Centre For Innovative Medicine, Vilnius, Lithuania., Henriksen PA; Edinburgh Heart Centre, Royal Infirmary of Edinburgh, Edinburgh, UK., Lenihan D; Cardio-Oncology Center of Excellence, Washington University in St Louis, St Louis, MO, USA., Dent S; Duke Cancer Institute, Duke University, Durham, NC, USA., Barac A; MedStar Heart and Vascular Institute, Georgetown University, Washington, DC, USA., Stanway S; Breast Unit, Royal Marsden Hospital, Surrey, UK., Moslehi J; Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Suter TM; Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland., Ky B; University of Pennsylvania, Philadelphia, PA, USA., Štěrba M; Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic., Cardinale D; Cardioncology Unit, European Institute of Oncology, IRCCS, Milan, Italy., Cohen-Solal A; UMR-S 942, Paris University, Cardiology Department, Lariboisiere Hospital, AP-HP, Paris, France., Tocchetti CG; Department of Translational Medical Sciences and Interdepartmental Center for Clinical and Translational Research (CIRCET), 'Federico II' University, Naples, Italy., Farmakis D; University of Cyprus Medical School, Nicosia, Cyprus.; Cardio-Oncology Clinic, Heart Failure Unit, 'Attikon' University Hospital, Athens, Greece.; National and Kapodistrian University of Athens Medical School, Athens, Greece., Bergler-Klein J; Department of Cardiology, Medical University of Vienna, Vienna, Austria., Anker MS; Division of Cardiology and Metabolism, Department of Cardiology, Charité and Berlin Institute of Health Center for Regenerative Therapies (BCRT) and DZHK (German Centre for Cardiovascular Research), partner site Berlin and Department of Cardiology, Charité Campus Benjamin Franklin, Berlin, Germany., Von Haehling S; Department of Cardiology and Pneumology, University of Goettingen Medical Center, Goettingen, Germany.; German Center for Cardiovascular Research (DZHK), partner site Goettingen, Goettingen, Germany., Belenkov Y; Sechenov Medical University, Moscow, Russia., Iakobishvili Z; Department of Community Cardiology, Tel Aviv Jaffa District, Clalit Health Fund and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Maack C; Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany., Ciardiello F; Department of Precision Medicine, 'Luigi Vanvitelli' University of Campania, Naples, Italy., Ruschitzka F; University Heart Center, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland., Coats AJS; University of Warwick, Warwick, UK.; Pharmacology Centre of Clinical and Experimental Medicine, IRCCS San Raffaele Pisana, Rome, Italy., Seferovic P; Faculty of Medicine and Serbian Academy of Sciences and Arts, University of Belgrade, Belgrade, Serbia., Lainscak M; University of Ljubljana, Ljubljana, Slovenia., Piepoli MF; Cardiac Department, 'Guglielmo da Saliceto' Polichirurgico Hospital AUSL Piacenza, Piacenza, Italy., Chioncel O; Emergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', Bucharest, Romania.; University of Medicine Carol Davila, Bucharest, Romania., Bax J; Department of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands., Hulot JS; Université de Paris, CIC1418, Paris Cardiovascular Research Center, INSERM, Paris, France., Skouri H; Cardiology Division, Internal Medicine Department at American University of Beirut Medical Center, Beirut, Lebanon., Hägler-Laube ES; Inselspital, University Hospital of Bern, Bern, Switzerland., Asteggiano R; Cardiologist in Practice, Turin, Italy., Fernandez TL; Cardiology Service, Cardio-Oncology Unit, La Paz University Hospital and IdiPAz Research Institute, Ciber CV, Madrid, Spain., de Boer RA; Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Lyon AR; Cardio-Oncology Service, Royal Brompton Hospital and Imperial College London, London, UK.
Jazyk: angličtina
Zdroj: European journal of heart failure [Eur J Heart Fail] 2020 Nov; Vol. 22 (11), pp. 1966-1983. Date of Electronic Publication: 2020 Oct 20.
DOI: 10.1002/ejhf.2017
Abstrakt: Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases in cardiac biomarkers including cardiac troponin and natriuretic peptides can be used to guide initiation of cardioprotective treatments for cancer patients during treatment and to monitor the response to cardioprotective treatments, and they also offer prognostic value. This position statement examines the role of cardiac biomarkers in the management of cancer patients. The Cardio-Oncology Study Group of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in collaboration with the Cardio-Oncology Council of the ESC have evaluated the current evidence for the role of cardiovascular biomarkers in cancer patients before, during and after cardiotoxic cancer therapies. The characteristics of the main two biomarkers troponin and natriuretic peptides are discussed, the link to the mechanisms of cardiovascular toxicity, and the evidence for their clinical use in surveillance during and after anthracycline chemotherapy, trastuzumab and HER2-targeted therapies, vascular endothelial growth factor inhibitors, proteasome inhibitors, immune checkpoint inhibitors, cyclophosphamide and radiotherapy. Novel surveillance clinical pathways integrating cardiac biomarkers for cancer patients receiving anthracycline chemotherapy or trastuzumab biomarkers are presented and future direction in cardio-oncology biomarker research is discussed.
(© 2020 European Society of Cardiology.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje